Übersicht der SEO Analyse
Metaangaben
80% 
Seitenqualität
68% 
Seitenstruktur
79% 
Verlinkung
25% 
Server
100% 
Externe Faktoren
100% 
SEO Score
Antwortzeit
0,23 s
Dateigröße
207,10 kB
Wörter
1273
Medien
22
Anzahl Links
349 Intern / 11 Extern

To-do Liste mit SEO Optimierungen

Meta-Angaben im HTML

Titel
(Extrem wichtig)
Novartis
Der Titel ist zu kurz. (76 Pixel von maximal 580 Pixel Länge) Jetzt optimieren
Der Seitentitel besteht nur aus einem Wort.
Es gibt keine Wortwiederholungen im Titel.
Meta-Description
(Extrem wichtig)
Working together, we can reimagine medicine to improve and extend people’s lives.
Die Meta-Description hat eine optimale Länge. (515 Pixel von maximal 1000 Pixel Länge)
Crawlbarkeit
(Extrem wichtig)
Es gibt keine Probleme beim Zugriff auf die Webseite.
Canonical Link
(Wichtig)
https://www.novartis.com/
Die Seite hat einen korrekten Canonical Link.
Sprache
(Wenig wichtig)
Im Text erkannte Sprache: en
Im HTML angegebene Sprache: en
Serverstandort: Vereinigte Staaten von Amerika
Die Sprache wird im HTML Code wie folgt angegeben: en
Alternate/Hreflang Links
(Wenig wichtig)
Die angegebenen Alternate Links sind fehlerfrei.
Weitere Metatags
(Wenig wichtig)
Es gibt keinen rel next Meta Tag auf der Seite.
Es gibt keinen rel prev Meta Tag auf der Seite.
Domain
(Wenig wichtig)
Die Domain ist keine Subdomain.
Die Länge der Domain ist gut.
Die Domain enthält keine Umlaute.
Seiten URL
(Wenig wichtig)
In der URL wurden keine Parameter entdeckt.
In der URL wurde keine Session ID entdeckt.
Die URL hat nicht zu viele Unterverzeichnisse.
Zeichensatzkodierung
(Wenig wichtig)
Die Angaben zur Zeichensatzkodierung (UTF-8) sind fehlerfrei.
Doctype
(Nice to have)
Die Doctype Angabe HTML 5 ist korrekt angegeben.
Die Doctype Angabe befindet sich an erster Stelle im HTML-Code.
Favicon
(Nice to have)
Das Favoriten Icon (Favicon) ist korrekt verlinkt.

Meta Tags

NameWert
descriptionWorking together, we can reimagine medicine to improve and extend people’s lives.
abstractWorking together, we can reimagine medicine to improve and extend people’s lives.
google-site-verificationMl04WfS7Ss3mQoi-HOUTHQazFh1Fl28fYjOLLtaJSLc
MobileOptimizedwidth
HandheldFriendlytrue
viewportwidth=device-width, initial-scale=1, shrink-to-fit=no
langen
twitter:cardsummary_large_image
twitter:descriptionWorking together, we can reimagine medicine to improve and extend people’s lives.
twitter:site@novartis
twitter:titleNovartis
twitter:site:id17226612
twitter:creator@novartis
twitter:creator:id17226612
twitter:urlhttps://www.novartis.com/home
twitter:imagehttps://www.novartis.com/sites/novartis_com/files/novartis-logo-open-graph.jpg
twitter:image:altNovartis logo
og:site_nameNovartis
og:typeWebsite
og:urlhttps://www.novartis.com/home
og:titleNovartis
og:descriptionWorking together, we can reimagine medicine to improve and extend people’s lives.
og:imagehttps://www.novartis.com/sites/novartis_com/files/2023-11/novartis-animated-logo-1x.gif
og:image:urlhttps://www.novartis.com/sites/novartis_com/files/2023-11/novartis-animated-logo-1x.gif
og:image:secure_urlhttps://www.novartis.com/sites/novartis_com/files/2023-11/novartis-animated-logo-1x.gif
og:image:altNovartis logo
x-dns-prefetch-controlon
x-ua-compatibleie=edge
charsetutf-8

Analysiere jetzt kostenlos bis zu 1.000 Unterseiten von novartis.com!

Kostenlos Testen
Die Nutzung des Basis Accounts ist zeitlich unbegrenzt möglich

Seitenqualität

Inhalt
(Extrem wichtig)
Wörter aus der H1 Überschrift werden nicht im Text der Seite verwendet.
Der Inhalt ist mit 1273 Wörtern in Ordnung.
Der Text besteht zu 15.1% aus Füllwörtern.
Im Text befindet sich eine Aufzählung, dies deutet auf eine gute Textstruktur hin.
Es wurden 13 Fließtextblöcke auf der Seite gefunden.
Es wurden keine Platzhalter Texte bzw. Bilder gefunden.
Es befinden sich keine Duplikate auf der Seite.
Die durchschnittliche Satzlänge ist mit 13.19 Wörtern gut.
Frames
(Extrem wichtig)
Die Seite hat kein Frameset.
Mobile
(Wenig wichtig)
Es ist kein Apple-Touch Icon angegeben.
Der angegebene Viewport (width=device-width, initial-scale=1, shrink-to-fit=no) ist korrekt.
Bold- und Strongtags
(Wenig wichtig)
Die Menge an Tags ist mit 129 sehr hoch. Wir empfehlen für diese Webseite die Verwendung von maximal 25 Tags.
Einige Tags werden wiederholt. z.B.: international
Bilder Optimierung
(Wenig wichtig)
Alle gefundenen Bilder haben Alt-Attribute. (Alternativer Bild Text)
Soziale Vernetzung
(Nice to have)
Es befinden sich wenige Social-Sharing Möglichkeiten auf der Seite. Mit Plugins zum Teilen kann die Reichweite der Seite in sozialen Netzwerken erhöht werden.
Zusätzliches Markup
(Nice to have)
Es wurde kein zusätzliches Markup gefunden.
HTTPS
(Wenig wichtig)
Die Seite verwendet HTTPS um Daten sicher zu übertragen.
Alle eingebundenen Dateien werden ebenfalls über HTTPS ausgeliefert.

Medienliste

URLALT-AttributeTitel
/themes/custom/polaris/logo.svgNovartisHome
.../polaris/patterns/images/icon-search.svgOpen
...m/polaris/patterns/images/icon-close.svgClose
...custom/polaris/patterns/images/globe.svglanguage-selector-globe
...custom/polaris/patterns/images/globe.svglanguage-selector-globe
...bed-kid-room-menu.jpg.webp?itok=KmIUz5U9Mother and daughter cuddling on a bed in a kids roomMother and daughter cuddling on a bed in a kids room
...ench-in-park-menu.jpg.webp?itok=5-8i5oYLAdult daughter talking to her senior parents on a bench in a parkAdult daughter talking to her senior parents on a bench in a park
...ood-pressure-menu.jpg.webp?itok=U5l7-GOFSmiling HCP taking senior patient's blood pressureSmiling HCP taking senior patient's blood pressure
...ientist-cambridge.jpg.webp?itok=_1WeOYMUA female research scientist in a lab looking at a sampleA female research scientist in a lab looking at a sample
...and-laughing-menu.jpg.webp?itok=fokSGWttGroup of warm clothed women, seated outside, smiling and laughingGroup of warm clothed women, seated outside, smiling and laughing
...ptop-on-sofa-menu.jpg.webp?itok=ipyWZ-o1Business woman working on her laptop in a bright atmosphereBusiness woman working on her laptop in a bright atmosphere
...11/news-hero-menu.jpg.webp?itok=STu25KS9Overhead view of a meeting room with people in the foreground and screens in the backgroundOverhead view of a meeting room with people in the foreground and screens in the background
...-people-mega-menu.jpg.webp?itok=hwenfnKhTwo business peopleTwo business people
...ing-on-beach-menu.jpg.webp?itok=xtSMUGvgGrandmother, mother and daughter smiling and laughing on a beachGrandmother, mother and daughter smiling and laughing on a beach
...laughing-on-beach.jpg.webp?itok=djN62APVGrandmother, mother and daughter smiling and laughing on a beachGrandmother, mother and daughter smiling and laughing on a beach
...hess-and-laughing.jpg.webp?itok=qlEDLubbTwo men, seated indoors around a table, engaged in a conversation and playing chessTwo men, seated indoors around a table, engaged in a conversation and playing chess
...ientist-cambridge.jpg.webp?itok=XGxCz1arA female research scientist in a lab looking at a sampleA female research scientist in a lab looking at a sample
...ling-and-laughing.jpg.webp?itok=wVBQo2cDGroup of warm clothed women, seated outside, smiling and laughingGroup of warm clothed women, seated outside, smiling and laughing
...024-media-content.jpg.webp?itok=qKxVa0EUQ3 2024Q3 2024
...ision-partnership.jpg.webp?itok=QjgsVT7vNovartis is an official partner of the Eurovision Song Contest 2025Novartis is an official partner of the Eurovision Song Contest 2025
...r-father-new-york.jpg.webp?itok=kGsAkDwDShanelle Gabriel spending time with her father in New YorkShanelle Gabriel spending time with her father in New York
...s-people-laughing.jpg.webp?itok=xyS0mD6NThree business people laughingThree business people laughing

Seitenstruktur

H1 Überschrift
(Extrem wichtig)
Reimagining medicine, together
Die H1-Überschrift ist perfekt.
Überschriften
(Wichtig)
Die Überschriftenstruktur ist fehlerhaft. Es sollte keine Hierarchie (H1-H6) ausgelassen werden.

Überschriftenstruktur

Überschriften HierarchieInhalt
H1 Reimagining medicine, together
H2 Novartis Financial Results – Q3 2024
H2 Official partner of the Eurovision Song Contest 2025
H2 Latest news
H2 Novartis in Society Integrated Report 2023
H2 Welcome to where we thrive together
H2 Resource links
H2 Novartis
H3 Discover our medicines
H3 Explore our science
H3 Learn about our impact
H3 Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
H3 Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
H3 Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
H6 Working together
H6 Topics
H6 Explore
H6 Therapeutic areas
H6 Footer Bottom
Einige der Linktexte der internen Links sind zu lang.
Einige der Linktexte wiederholen sich.
Die Anzahl an internen Links ist ok.
Alle internen Links haben keine dynamischen Parameter.
Es befinden sich 11 externe Links auf der Seite.
LinkAttributeLinktext
https://www.novartis.com/Anchor Skip to main content
https://www.novartis.com/IMG-ALT Novartis
https://www.novartis.com/Anchor International
https://www.novartis.com/Anchor Americas
https://www.novartis.com/Anchor Asia Pacific
https://www.novartis.com/Anchor Europe
https://www.novartis.com/Anchor Middle East & Africa
https://www.novartis.com/Subdomain Global | English
https://www.novartisfoundation...Extern Subdomain Novartis Foundation | English
https://www.novartis.com/ar-es/Subdomain Argentina | Español
https://www.novartis.com/br-pt/Subdomain Brazil | Português
https://www.novartis.com/ca-en/Subdomain Canada | English
https://www.novartis.com/ca-fr/Subdomain Canada | Français
/candean-es/Subdomain Central America | Español
https://www.novartis.com/co-es/Subdomain Colombia | Español
https://www.novartis.com/mx-es/Subdomain Mexico | Español
https://www.novartis.com/us-en/Subdomain United States | English
https://www.novartis.com/au-en/Subdomain Australia | English
https://www.novartis.com/bd-en/Subdomain Bangladesh | English
https://www.novartis.com/hk-zh/Subdomain Hong Kong S.A.R. | 繁體中文
https://www.novartis.com/in-en/Subdomain India | English
https://www.novartis.com/id-en/Subdomain Indonesia | English
https://www.novartis.com/jp-ja/Subdomain Japan | 日本語
https://www.novartis.com/kr-ko/Subdomain Korea | 한국어
https://www.novartis.com.cn/Extern Subdomain Mainland China | 中文
https://www.novartis.com/my-en/Subdomain Malaysia | English
https://www.novartis.com/pk-en/Subdomain Pakistan | English
https://www.novartis.com/ph-en/Subdomain Philippines | English
https://www.novartis.com/sg-en/Subdomain Singapore | English
https://www.novartis.com/tw-zh/Subdomain Taiwan | 繁體中文
https://www.novartis.com/th-th/Subdomain Thailand | ภาษาไทย
https://www.novartis.com/at-de/Subdomain Austria | Deutsch
https://www.novartis.com/be-fr/Subdomain Belgium | Français
https://www.novartis.com/be-nl/Subdomain Belgium | Nederlands
https://www.novartis.com/bg-bg/Subdomain Bulgaria | Български
https://www.novartis.com/cz-cs/Subdomain Czech Republic | Česky
https://www.novartis.com/cz-en/Subdomain Czech Republic | English
https://www.novartis.com/dk-da/Subdomain Denmark | Dansk
https://www.novartis.com/ee-et/Subdomain Estonia | Eesti
https://www.novartis.com/fi-fi/Subdomain Finland | Suomalainen
https://www.novartis.com/fr-fr/Subdomain France | Français
https://www.novartis.com/de-de/Subdomain Germany | Deutsch
https://www.novartis.com/gr-el/Subdomain Greece | Ελληνικά
https://www.novartis.com/hu-hu/Subdomain Hungary | Magyar
https://www.novartis.com/ie-en/Subdomain Ireland | English
https://www.novartis.com/it-it/Subdomain Italy | Italiano
https://www.novartis.com/lv-lv/Subdomain Latvia | Latvian
https://www.novartis.com/lt-lt/Subdomain Lithuania | Lithuanian
https://www.novartis.com/nl-nl/Subdomain Netherlands | Nederlands
https://www.novartis.com/no-no/Subdomain Norway | Norsk
https://www.novartis.com/pl-pl/Subdomain Poland | Polski
https://www.novartis.com/pt-pt/Subdomain Portugal | Português
https://www.novartis.com/ro-ro/Subdomain Romania | Română
https://www.novartis.com/ru-ru/Subdomain Russia | Русский
https://www.novartis.com/rs-sr/Subdomain Serbia | Srpski
https://www.novartis.com/sk-sk/Subdomain Slovakia | Slovensky
https://www.novartis.com/si-sl/Subdomain Slovenia | Slovenščina
https://www.novartis.com/si-en/Subdomain Slovenia | English
https://www.novartis.com/es-es/Subdomain Spain | Español
https://www.novartis.com/se-se/Subdomain Sweden | Svenska
https://www.novartis.com/ch-de/Subdomain Switzerland | Deutsch
https://www.novartis.com/ch-fr/Subdomain Switzerland | Français
https://www.novartis.com/tr-tr/Subdomain Türkiye | Türkçe
https://www.novartis.com/uk-en/Subdomain United Kingdom | English
https://www.novartis.com/eg-en/Subdomain Egypt | English
https://www.novartis.com/il-he/Subdomain Israel | עברית
https://www.novartis.com/sa-ar/Subdomain Saudi Arabia | العربية
https://www.novartis.com/za-en/Subdomain South Africa | English
https://www.novartis.com/Anchor Textduplikat International
https://www.novartis.com/Anchor Textduplikat Americas
https://www.novartis.com/Anchor Textduplikat Asia Pacific
https://www.novartis.com/Anchor Textduplikat Europe
https://www.novartis.com/Anchor Textduplikat Middle East & Africa
https://www.novartis.com/ar-es/Subdomain Textduplikat Argentina | Español
https://www.novartis.com/au-en/Subdomain Textduplikat Australia | English
https://www.novartis.com/at-de/Subdomain Textduplikat Austria | Deutsch
https://www.novartis.com/bd-en/Subdomain Textduplikat Bangladesh | English
https://www.novartis.com/be-fr/Subdomain Textduplikat Belgium | Français
https://www.novartis.com/be-nl/Subdomain Textduplikat Belgium | Nederlands
https://www.novartis.com/br-pt/Subdomain Textduplikat Brazil | Português
https://www.novartis.com/bg-bg/Subdomain Textduplikat Bulgaria | Български
https://www.novartis.com/ca-en/Subdomain Textduplikat Canada | English
https://www.novartis.com/ca-fr/Subdomain Textduplikat Canada | Français
/candean-es/Subdomain Textduplikat Central America | Español
https://www.novartis.com/co-es/Subdomain Textduplikat Colombia | Español
https://www.novartis.com/cz-cs/Subdomain Textduplikat Czech Republic | Česky
https://www.novartis.com/cz-en/Subdomain Textduplikat Czech Republic | English
https://www.novartis.com/dk-da/Subdomain Textduplikat Denmark | Dansk
https://www.novartis.com/eg-en/Subdomain Textduplikat Egypt | English
https://www.novartis.com/ee-et/Subdomain Textduplikat Estonia | Eesti
https://www.novartis.com/fi-fi/Subdomain Textduplikat Finland | Suomalainen
https://www.novartis.com/fr-fr/Subdomain Textduplikat France | Français
https://www.novartis.com/de-de/Subdomain Textduplikat Germany | Deutsch
https://www.novartis.com/gr-el/Subdomain Textduplikat Greece | Ελληνικά
https://www.novartis.com/hk-zh/Subdomain Textduplikat Hong Kong S.A.R. | 繁體中文
https://www.novartis.com/hu-hu/Subdomain Textduplikat Hungary | Magyar
https://www.novartis.com/in-en/Subdomain Textduplikat India | English
https://www.novartis.com/id-en/Subdomain Textduplikat Indonesia | English
https://www.novartis.com/ie-en/Subdomain Textduplikat Ireland | English
https://www.novartis.com/il-he/Subdomain Textduplikat Israel | עברית
https://www.novartis.com/it-it/Subdomain Textduplikat Italy | Italiano
https://www.novartis.com/jp-ja/Subdomain Textduplikat Japan | 日本語
https://www.novartis.com/kr-ko/Subdomain Textduplikat Korea | 한국어
https://www.novartis.com/lv-lv/Subdomain Textduplikat Latvia | Latvian
https://www.novartis.com/lt-lt/Subdomain Textduplikat Lithuania | Lithuanian
https://www.novartis.com.cn/Extern Subdomain Textduplikat Mainland China | 中文
https://www.novartis.com/my-en/Subdomain Textduplikat Malaysia | English
https://www.novartis.com/mx-es/Subdomain Textduplikat Mexico | Español
https://www.novartis.com/nl-nl/Subdomain Textduplikat Netherlands | Nederlands
https://www.novartis.com/no-no/Subdomain Textduplikat Norway | Norsk
https://www.novartis.com/Subdomain Textduplikat Global | English
https://www.novartisfoundation...Extern Subdomain Textduplikat Novartis Foundation | English
https://www.novartis.com/pk-en/Subdomain Textduplikat Pakistan | English
https://www.novartis.com/ph-en/Subdomain Textduplikat Philippines | English
https://www.novartis.com/pl-pl/Subdomain Textduplikat Poland | Polski
https://www.novartis.com/pt-pt/Subdomain Textduplikat Portugal | Português
https://www.novartis.com/ro-ro/Subdomain Textduplikat Romania | Română
https://www.novartis.com/ru-ru/Subdomain Textduplikat Russia | Русский
https://www.novartis.com/sa-ar/Subdomain Textduplikat Saudi Arabia | العربية
https://www.novartis.com/rs-sr/Subdomain Textduplikat Serbia | Srpski
https://www.novartis.com/sg-en/Subdomain Textduplikat Singapore | English
https://www.novartis.com/sk-sk/Subdomain Textduplikat Slovakia | Slovensky
https://www.novartis.com/si-sl/Subdomain Textduplikat Slovenia | Slovenščina
https://www.novartis.com/si-en/Subdomain Textduplikat Slovenia | English
https://www.novartis.com/za-en/Subdomain Textduplikat South Africa | English
https://www.novartis.com/es-es/Subdomain Textduplikat Spain | Español
https://www.novartis.com/se-se/Subdomain Textduplikat Sweden | Svenska
https://www.novartis.com/ch-de/Subdomain Textduplikat Switzerland | Deutsch
https://www.novartis.com/ch-fr/Subdomain Textduplikat Switzerland | Français
https://www.novartis.com/tw-zh/Subdomain Textduplikat Taiwan | 繁體中文
https://www.novartis.com/th-th/Subdomain Textduplikat Thailand | ภาษาไทย
https://www.novartis.com/tr-tr/Subdomain Textduplikat Türkiye | Türkçe
https://www.novartis.com/uk-en/Subdomain Textduplikat United Kingdom | English
https://www.novartis.com/us-en/Subdomain Textduplikat United States | English
https://www.novartis.com/aboutAbout
A-TITLE About
/about/board-directorsBoard of Directors
A-TITLE Board of Directors
/about/board-directors/joerg-r...Joerg Reinhardt
A-TITLE Joerg Reinhardt
/about/board-directors/simon-m...Simon Moroney
A-TITLE Simon Moroney
/about/board-directors/nancy-c...Nancy C. Andrews
A-TITLE Nancy C. Andrews
/about/board-directors/ton-bue...Ton Buechner
A-TITLE Ton Buechner
/about/board-directors/patrice...Patrice Bula
A-TITLE Patrice Bula
/about/board-directors/elizabe...Elizabeth (Liz) Doherty
A-TITLE Elizabeth (Liz) Doherty
/about/board-directors/ana-de-...Ana de Pro Gonzalo
A-TITLE Ana de Pro Gonzalo
/about/board-directors/bridget...Bridgette Heller
A-TITLE Bridgette Heller
/about/board-directors/daniel-...Daniel Hochstrasser
A-TITLE Daniel Hochstrasser
/about/board-directors/frans-v...Frans van Houten
A-TITLE Frans van Houten
/about/board-directors/charles...Charles L. Sawyers
A-TITLE Charles L. Sawyers
/about/board-directors/william...William T. Winters
A-TITLE William T. Winters
/about/board-directors/john-d-...John D. Young
A-TITLE John D. Young
/about/board-directors/charlot...Charlotte Pamer-Wieser
A-TITLE Charlotte Pamer-Wieser
/about/executive-committeeExecutive Committee
A-TITLE Executive Committee
/about/executive-committee/vas...Vasant (Vas) Narasimhan
A-TITLE Vasant (Vas) Narasimhan
/about/executive-committee/shr...Shreeram Aradhye
A-TITLE Shreeram Aradhye
/about/executive-committee/vic...Victor Bulto
A-TITLE Victor Bulto
/about/executive-committee/aha...Aharon (Ronny) Gal
A-TITLE Aharon (Ronny) Gal
/about/executive-committee/kar...Karen L. Hale
A-TITLE Karen L. Hale
/about/executive-committee/pat...Patrick Horber
A-TITLE Patrick Horber
/about/executive-committee/har...Harry Kirsch
A-TITLE Harry Kirsch
/about/executive-committee/rob...Rob Kowalski
A-TITLE Rob Kowalski
/about/executive-committee/ste...Steffen Lang
A-TITLE Steffen Lang
/about/executive-committee/fio...Fiona Marshall
A-TITLE Fiona Marshall
/about/executive-committee/kla...Klaus Moosmayer
A-TITLE Klaus Moosmayer
/about/executive-committee/lut...Lutz Hegemann
A-TITLE Lutz Hegemann
/about/executive-committee/kee...Kees Roks
A-TITLE Kees Roks
/about/executive-committee/mic...Michelle Weese
A-TITLE Michelle Weese
/about/productsProducts
A-TITLE Products
/about/therapeutic-areasTherapeutic areas
A-TITLE Therapeutic areas
/about/therapeutic-areas/cardi...Cardiovascular, renal and metabolic
A-TITLE Cardiovascular, renal and metabolic
/about/therapeutic-areas/immun...Immunology
A-TITLE Immunology
/about/therapeutic-areas/neuro...Neuroscience
A-TITLE Neuroscience
/about/therapeutic-areas/oncologyOncology
A-TITLE Oncology
/about/people-and-culturePeople and culture
A-TITLE People and culture
/about/diversity-equity-and-in...Diversity, equity and inclusion
A-TITLE Diversity, equity and inclusion
/about/diversity-equity-and-in...Equity
A-TITLE Equity
/about/diversity-equity-and-in...Inclusivity
A-TITLE Inclusivity
/about/diversity-equity-and-in...Parental leave
A-TITLE Parental leave
/about/diversity-equity-and-in...Society
A-TITLE Society
/about/novartis-gene-therapiesNovartis Gene Therapies
A-TITLE Novartis Gene Therapies
/about/manufacturingManufacturing
A-TITLE Manufacturing
/about/qualityQuality
A-TITLE Quality
/about/quality/audit-programAudit program
A-TITLE Audit program
/about/quality/novartis-qualit...Novartis quality management system (QMS)
A-TITLE Novartis quality management system (QMS)
/about/quality/product-and-pat...Product and patient safety training
A-TITLE Product and patient safety training
/about/quality/regulatory-insp...Regulatory inspections
A-TITLE Regulatory inspections
/about/quality/product-recallsProduct recalls
A-TITLE Product recalls
/about/quality/third-party-sup...Third-party suppliers
A-TITLE Third-party suppliers
/about/awards-and-recognitionAwards and recognition
A-TITLE Awards and recognition
/patients-and-caregiversPatients and caregivers
A-TITLE Patients and caregivers
/patients-and-caregivers/novar...Novartis commitment to patients and caregivers
A-TITLE Novartis commitment to patients and caregivers
https://www.novartis.com/diseasesDiseases
A-TITLE Diseases
/investors/reporting-and-trans...Patient organization funding
A-TITLE Patient organization funding
/news/stories/patient-perspect...Patients perspectives stories
A-TITLE Patients perspectives stories
/healthcare-professionalsHealthcare professionals
A-TITLE Healthcare professionals
/healthcare-professionals/medi...Medical congresses and events
A-TITLE Medical congresses and events
/healthcare-professionals/medi...ASCO Annual Meeting
A-TITLE ASCO Annual Meeting
/about/productsTextduplikat Products
A-TITLE Products
/research-development/novartis...Novartis pipeline
A-TITLE Novartis pipeline
/healthcare-professionals/mana...Managed access programs
A-TITLE Managed access programs
/healthcare-professionals/mana...Zolgensma® Global Managed Access Program (gMAP)
A-TITLE Zolgensma® Global Managed Access Program (gMAP)
/healthcare-professionals/nova...Novartis external funding
A-TITLE Novartis external funding
/healthcare-professionals/heal...Healthcare professional resources by country
A-TITLE Healthcare professional resources by country
/healthcare-professionals/inve...Investigator-initiated trials / studies
A-TITLE Investigator-initiated trials / studies
/healthcare-professionals/nova...Novartis medical information
A-TITLE Novartis medical information
/healthcare-professionals/nova...Submit medical enquiry
A-TITLE Submit medical enquiry
/research-and-developmentResearch and development
A-TITLE Research and development
/research-and-development/tech...Technology platforms
A-TITLE Technology platforms
/research-and-development/rese...Research disease areas
A-TITLE Research disease areas
/research-and-development/rese...Cardiovascular and metabolic disease research at Novartis
A-TITLE Cardiovascular and metabolic disease research at Novartis
/research-and-development/rese...DAx: exploratory disease research at Novartis
A-TITLE DAx: exploratory disease research at Novartis
/research-and-development/rese...Global Health disease area research at Novartis
A-TITLE Global Health disease area research at Novartis
/research-and-development/rese...Immunology disease research at Novartis
A-TITLE Immunology disease research at Novartis
/research-and-development/rese...Neuroscience research at Novartis
A-TITLE Neuroscience research at Novartis
/research-and-development/rese...Oncology research at Novartis
A-TITLE Oncology research at Novartis
/research-and-development/rese...Ophthalmology research at Novartis
A-TITLE Ophthalmology research at Novartis
/research-development/novartis...Textduplikat Novartis pipeline
A-TITLE Novartis pipeline
/research-and-development/rese...Research collaborations
A-TITLE Research collaborations
/research-and-development/coll...Collaborations
A-TITLE Collaborations
https://www.novartis.com/esgESG
A-TITLE ESG
/esg/accessAccess
A-TITLE Access
/esg/access/creating-sustainab...Creating sustainable business models
A-TITLE Creating sustainable business models
/esg/access/value-based-pricingValue-based pricing
A-TITLE Value-based pricing
/esg/access/sub-saharan-africaSub-Saharan Africa
A-TITLE Sub-Saharan Africa
/esg/access/donationsDonations
A-TITLE Donations
/esg/access/novartis-access-pr...Novartis access principles
A-TITLE Novartis access principles
/esg/access/novartis-oncology-...Novartis oncology access
A-TITLE Novartis oncology access
/esg/access/patents-and-licensingPatents and licensing
A-TITLE Patents and licensing
/esg/environmental-sustainabilityEnvironmental sustainability
A-TITLE Environmental sustainability
/esg/environmental-sustainabil...Climate
A-TITLE Climate
/esg/environmental-sustainabil...Waste
A-TITLE Waste
/esg/environmental-sustainabil...Water
A-TITLE Water
/esg/ethics-risk-and-complianceEthics, risk and compliance
A-TITLE Ethics, risk and compliance
/esg/ethics-risk-and-complianc...Ethical behavior
A-TITLE Ethical behavior
/esg/ethics-risk-and-complianc...Compliance
A-TITLE Compliance
/esg/ethics-risk-and-complianc...Human rights
A-TITLE Human rights
/esg/ethics-risk-and-complianc...Learning and engagement
A-TITLE Learning and engagement
/esg/ethics-risk-and-complianc...Integrated risk assurance
A-TITLE Integrated risk assurance
/esg/global-healthGlobal health
A-TITLE Global health
/esg/global-health/pandemic-pr...Pandemic preparedness
A-TITLE Pandemic preparedness
/esg/global-health/avoidable-b...Avoidable blindness
A-TITLE Avoidable blindness
/diseases/chagas-diseaseChagas disease
A-TITLE Chagas disease
/diseases/leprosyLeprosy
A-TITLE Leprosy
/diseases/malariaMalaria
A-TITLE Malaria
/diseases/sickle-cell-diseaseSickle cell disease (SCD)
A-TITLE Sickle cell disease (SCD)
https://www.novartisfoundation...Neues Fenster Extern Subdomain Novartis Foundation
A-TITLE Novartis Foundation
/about/diversity-equity-and-in...Textduplikat Diversity, equity and inclusion
A-TITLE Diversity, equity and inclusion
/esg/indexESG index
A-TITLE ESG index
/investors/reporting-and-trans...Reporting and transparency hub
A-TITLE Reporting and transparency hub
/investors/reporting-and-trans...Novartis in Society Integrated Report
A-TITLE Novartis in Society Integrated Report
/investors/reporting-and-trans...ESG rating performance
A-TITLE ESG rating performance
/investors/reporting-and-trans...Targets
A-TITLE Targets
/investors/reporting-and-trans...Textduplikat Patient organization funding
A-TITLE Patient organization funding
/investors/reporting-and-trans...Payments to healthcare professionals
A-TITLE Payments to healthcare professionals
/investors/reporting-and-trans...Public policy
A-TITLE Public policy
/investors/reporting-and-trans...A living wage
A-TITLE A living wage
/investors/reporting-and-trans...A safe workplace
A-TITLE A safe workplace
/investors/reporting-and-trans...Animal research
A-TITLE Animal research
/investorsInvestors
A-TITLE Investors
/investors/event-calendarEvent calendar
A-TITLE Event calendar
/investors/financial-dataFinancial data
A-TITLE Financial data
/investors/financial-data/annu...Novartis annual results
A-TITLE Novartis annual results
/investors/financial-data/quar...Novartis quarterly results
A-TITLE Novartis quarterly results
/investors/financial-data/sec-...Novartis SEC filings
A-TITLE Novartis SEC filings
/investors/financial-data/prod...Product sales
A-TITLE Product sales
/investors/financial-data/fixe...Fixed-income securities
A-TITLE Fixed-income securities
/investors/financial-data/expe...Expected currency impact
A-TITLE Expected currency impact
/investors/share-data-analysisShare data and analysis
A-TITLE Share data and analysis
/investors/share-data-and-anal...Share monitor
A-TITLE Share monitor
/investors/share-data-and-anal...Dividend information
A-TITLE Dividend information
/investors/share-data-and-anal...Share ownership
A-TITLE Share ownership
/investors/share-data-analysis...Share overview
A-TITLE Share overview
/investors/share-data-and-anal...Return on investment calculator
A-TITLE Return on investment calculator
/investors/shareholder-informa...Shareholder information
A-TITLE Shareholder information
/investors/shareholder-informa...General Meetings
A-TITLE General Meetings
/investors/shareholder-informa...American Depositary Receipts (ADR)
A-TITLE American Depositary Receipts (ADR)
/investors/shareholder-informa...Share buyback
A-TITLE Share buyback
/investors/shareholder-informa...Frequently asked questions
A-TITLE Frequently asked questions
/investors/company-overviewCompany overview
A-TITLE Company overview
/investors/company-overview/co...Corporate governance
A-TITLE Corporate governance
/investors/reporting-and-trans...Textduplikat Reporting and transparency hub
A-TITLE Reporting and transparency hub
/investors/reporting-and-trans...Textduplikat Novartis in Society Integrated Report
A-TITLE Novartis in Society Integrated Report
/investors/reporting-and-trans...Reporting archive
A-TITLE Reporting archive
/investors/reporting-and-trans...Textduplikat ESG rating performance
A-TITLE ESG rating performance
/news/stay-up-to-datePublications order form
A-TITLE Publications order form
https://www.novartis.com/esgTextduplikat ESG
A-TITLE ESG
https://www.novartis.com/newsNews
A-TITLE News
/news/news-archiveNews archive
A-TITLE News archive
/news/media-libraryMedia library
A-TITLE Media library
https://www.novartis.com/storiesStories
A-TITLE Stories
/news/stay-up-to-dateSubscribe
A-TITLE Subscribe
/news/eventsEvents
A-TITLE Events
https://www.novartis.com/careersCareers
A-TITLE Careers
/careers/career-searchCareer search
A-TITLE Career search
/careers/our-business-functionsOur business functions
A-TITLE Our business functions
/careers/our-business-function...Careers in research and development
A-TITLE Careers in research and development
/careers/our-business-function...Careers in operations
A-TITLE Careers in operations
/careers/our-business-function...Careers in commercial and sales
A-TITLE Careers in commercial and sales
/careers/our-business-function...Careers in global functions
A-TITLE Careers in global functions
/careers/why-novartisWhy Novartis
A-TITLE Why Novartis
/careers/career-hubCareer hub
A-TITLE Career hub
https://novartis.willhire.co/Neues Fenster Extern Subdomain Temporary contracts
A-TITLE Temporary contracts
/careers/early-careersEarly careers
A-TITLE Early careers
/careers/early-careers/graduatesGraduates
A-TITLE Graduates
/careers/early-careers/studentsStudents
A-TITLE Students
/careers/early-careers/us-biom...US Biomedical Research internship programs
A-TITLE US Biomedical Research internship programs
/careers/early-careers/communi...Community exploration and learning lab (CELL)
A-TITLE Community exploration and learning lab (CELL)
/clinicaltrialsClinical trials
A-TITLE Clinical trials
/partneringPartnering
A-TITLE Partnering
/supplier-portalSupplier portal
A-TITLE Supplier portal
https://www.novartis.com/reportNeues Fenster Report side effects
A-TITLE Report side effects
https://www.novartis.com/contactsContacts
A-TITLE Contacts
/about/therapeutic-areasDiscover our medicines Our innovative medicines address society’s greatest disease burdens and restore possibility for patients.
IMG-ALT Two men, seated indoors around a table, engaged in a conversation and playing chess
/research-and-developmentExplore our science Discover how we unravel the mysteries of biology and develop new technologies to fight disease and change lives.
IMG-ALT A female research scientist in a lab looking at a sample
/news/events/novartis-financia...Learn more
A-TITLE Learn more
/news/official-partner-eurovis...Textduplikat Learn more
A-TITLE Learn more
/news/media-releases/novartis-...Oct 29, 2024 Media Release Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
/news/media-releases/novartis-...Oct 29, 2024 Media Release Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milesto...
/news/media-releases/novartis-...Oct 27, 2024 Media Release Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
/news/news-archiveAll news
A-TITLE All news
/investors/reporting-and-trans...View the online summary
A-TITLE View the online summary
https://www.novartis.com/careersWelcome to where we thrive together
A-TITLE Welcome to where we thrive together
https://www.novartis.com/careersJoin us
A-TITLE Join us
https://www.novartis.com/aboutAbout Novartis
A-TITLE About Novartis
/healthcare-professionalsTextduplikat Healthcare professionals
A-TITLE Healthcare professionals
/patients-and-caregiversTextduplikat Patients and caregivers
A-TITLE Patients and caregivers
/research-development/novartis...Pipeline
A-TITLE Pipeline
/about/productsTextduplikat Products
A-TITLE Products
/patients-and-caregiversTextduplikat Patients and caregivers
/healthcare-professionalsTextduplikat Healthcare professionals
/research-and-developmentResearchers
https://www.novartis.com/careersJob seekers
https://www.novartis.com/newsJournalists
/investorsTextduplikat Investors
/news/events/novartis-financia...Q3 2024
/esg/accessTextduplikat Access
/about/diversity-equity-and-in...Diversity
https://www.novartis.com/esgTextduplikat ESG
/esg/ethics-risk-and-complianc...SpeakUp
/research-development/novartis...Textduplikat Pipeline
/about/productsTextduplikat Products
/clinicaltrialsTextduplikat Clinical trials
/partneringTextduplikat Partnering
https://www.novartis.com/storiesTextduplikat Stories
/about/therapeutic-areas/cardi...Textduplikat Cardiovascular, renal and metabolic
/about/therapeutic-areas/immun...Textduplikat Immunology
/about/therapeutic-areas/neuro...Textduplikat Neuroscience
/about/therapeutic-areas/oncologyTextduplikat Oncology
https://www.linkedin.com/compa...Neues Fenster Extern Subdomain A-TITLE LinkedIn
https://www.facebook.com/novartisNeues Fenster Extern Subdomain A-TITLE Facebook
https://x.com/novartisNeues Fenster Extern A-TITLE X formerly known as Twitter
https://www.instagram.com/nova...Neues Fenster Extern Subdomain A-TITLE Instagram
https://www.youtube.com/user/n...Neues Fenster Extern Subdomain A-TITLE Youtube
/terms-useTerms of use
https://www.novartis.com/privacyPrivacy
https://www.novartis.com/Anchor Cookie settings
https://www.novartis.com/contactsTextduplikat Contacts
/about/locationsLocations
/sitemap.xmlSite map
/open-sourceOpen source
/accessibilityWeb accessibility
/novartis-directoryNovartis Site Directory
A-TITLE Novartis Site Directory

Serverkonfiguration

HTTP-Weiterleitungen
(Extrem wichtig)
Die Seite leitet weiter auf "https://www.novartis.com/"
HTTP-Header
(Wichtig)
Es wird kein X-Powered HTTP-Header mitgesendet.
Der Webserver nutzt GZip zur komprimierten Übertragung der Webseite (HTML).
Performance
(Wenig wichtig)
Die Antwortzeit der HTML-Seite ist mit 0,23 Sekunden unter der Zielmarke von 0,40 Sekunden.
Die Dateigröße des HTML-Dokuments ist mit 207 kB in Ordnung.

HTTP-Header

NameWert
dateSun, 10 Nov 2024 19:17:32 GMT
content-typetext/html; charset=UTF-8
cache-controlmax-age=60, public, s-maxage=2628000, stale-if-error=180, stale-while-revalidate=180
content-languageen
x-content-type-optionsnosniff
x-frame-optionsSAMEORIGIN
expiresSun, 19 Nov 1978 05:00:00 GMT
last-modifiedSun, 10 Nov 2024 00:00:37 GMT
varyCookie,Accept-Encoding
content-security-policy-report-onlyscript-src 'self' 'unsafe-inline' 'unsafe-eval' https://unpkg.com https://acsbapp.com https://snap.licdn.com https://sc-static.net https://tr.snapchat.com https://maps.googleapis.com https://static.ads-twitter.com https://analytics.twitter.com https://connect.facebook.net https://cdn.cookielaw.org https://www.youtube.com https://static.addtoany.com https://cdnjs.cloudflare.com https://www.googletagmanager.com https://js-agent.newrelic.com https://geolocation.onetrust.com https://bam-cell.nr-data.net https://cdnsecakmi.kaltura.com https://cdnapisec.kaltura.com http://cdnapi.kaltura.com https://www.google-analytics.com https://cdn.jsdelivr.net https://script.crazyegg.com https://static.cloudflareinsights.com https://www.google.com https://www.gstatic.com https://bam.nr-data.net https://hm.baidu.com/hm.js https://www.clarity.ms https://www.googleadservices.com blob:; object-src 'self' 'unsafe-inline' 'unsafe-eval' https: data; style-src 'self' 'unsafe-inline' 'unsafe-eval' https://cdn.cookielaw.org https://acsbapp.com https://sc-static.net https://tr.snapchat.com https://maps.googleapis.com https://fonts.googleapis.com https://www.youtube.com https://static.addtoany.com https://cdnjs.cloudflare.com https://www.googletagmanager.com https://js-agent.newrelic.com https://geolocation.onetrust.com https://bam-cell.nr-data.net https://script.crazyegg.com https://static.cloudflareinsights.com https://cdnapisec.kaltura.com; frame-ancestors self; report-uri /report-csp-violation
x-xss-protection1; mode=block
strict-transport-securitymax-age=31536000; includeSubDomains
x-request-idv-d0f260d2-9ef6-11ef-82ff-97dc6b406443
x-ah-environmentprod
age1030
viavarnish
x-cacheHIT
x-cache-hits1040
cf-cache-statusHIT
server-timingcfCacheStatus;desc="HIT"
servercloudflare
cf-ray8e08621bdee86949-FRA
content-encodinggzip
statuscode200
http_versionHTTP/2

Externe Faktoren

Die Seite wird von Wikipedia verlinkt.
Die Seite ist exzellent von anderen Webseiten verlinkt.
Die Seite hat Backlinks von 15.636 verweisenden Domains.
Die Seite hat insgesamt 1.343.029 Backlinks.
Die Seite hat Backlinks von 10.876 verschiedenen IP Adressen.

Robots.txt

#
# robots.txt
#
# This file is to prevent the crawling and indexing of certain parts
# of your site by web crawlers and spiders run by sites like Yahoo!
# and Google. By telling these "robots" where not to go on your site,
# you save bandwidth and server resources.
#
# This file will be ignored unless it is at the root of your host:
# Used:    http://example.com/robots.txt
# Ignored: http://example.com/site/robots.txt
#
# For more information about the robots.txt standard, see:
# http://www.robotstxt.org/robotstxt.html

User-agent: *
# CSS, JS, Images
Allow: /core/*.css$
Allow: /core/*.css?
Allow: /core/*.js$
Allow: /core/*.js?
Allow: /core/*.gif
Allow: /core/*.jpg
Allow: /core/*.jpeg
Allow: /core/*.png
Allow: /core/*.svg
Allow: /profiles/*.css$
Allow: /profiles/*.css?
Allow: /profiles/*.js$
Allow: /profiles/*.js?
Allow: /profiles/*.gif
Allow: /profiles/*.jpg
Allow: /profiles/*.jpeg
Allow: /profiles/*.png
Allow: /profiles/*.svg
# Directories
Disallow: /core/
Disallow: /profiles/
# Files

Disallow: /web.config
# Paths (clean URLs)

Disallow: /comment/reply/
Disallow: /filter/tips

Disallow: /search/




# Paths (no clean URLs)

Disallow: /index.php/comment/reply/
Disallow: /index.php/filter/tips

Disallow: /index.php/search/




Disallow: /*printable
Disallow: /de-de/sites/novartis_de/files/*FAQ*
Disallow: /de-de/sites/novartis_de/files/*RMP*
Disallow: /de-de/sites/novartis_de/files/*FAQ*
Disallow: /de-de/sites/novartis_de/files/*RMP*
Disallow: /*/spc/*FAQ*
Disallow: /*/spc/*RMP*
Disallow: /*FAQ*
Disallow: /*RMP*

User-agent: GPTBot
Crawl-delay: 2

User-agent: bingbot
Crawl-delay: 2

User-agent: GoogleOther
Crawl-delay: 2

Suchvorschau

www.novartis.com
Novartis
Working together, we can reimagine medicine to improve and extend people’s lives.

Wichtigste Suchbegriffe

Folgende Keywords wurden erkannt. Überprüfe die Optimierung dieser Keywords für Deine Seite.

KeywordErgebnisPrüfen
Novartis72%Check
medicine66%Check
reimagine medicine58%Check
Novartis Society56%Check
Working54%Check
Novartis Foundation54%Check
People52%Check
extend people49%Check
Q3 202448%Check
Novartis Society Integrated47%Check

Analysiere jetzt kostenlos bis zu 1.000 Unterseiten von novartis.com!

Kostenlos Testen
Die Nutzung des Basis Accounts ist zeitlich unbegrenzt möglich

Cookie Einstellungen

Wir verwenden Cookies, damit unsere Website funktioniert und auch für Analyse- und Werbezwecke. Du kannst optionale Cookies selbstverständlich auch deaktivieren, siehe die folgenden Links für weitere Informationen.

Diese Cookies werden für grundlegende Websitefunktionen benötigt.

Damit wir besser verstehen, wie Besucher unsere Website nutzen.

Damit wir für Dich passgenaue Angebote bereitstellen können.